Ceritinib is an Orally Active ALK Tyrosine Kinase Inhibitor for Kinds of Cancers Research
Ceritinib is an orally active ALK tyrosine kinase inhibitor for kinds of cancers research.
Ceritinib is an orally active ALK tyrosine kinase inhibitor for kinds of cancers research.
TTT-3002, a tyrosine kinase inhibitor is one of the most potent FLT3 inhibitors. FLT3 (Fms-like tyrosine kinase 3, CD135) is a cytokine receptor that belongs to the receptor tyrosine kinase…
Growth factors and their transmembrane receptor tyrosine kinase play important roles in cell proliferation, survival, migration, and differentiation. Additionally, Epidermal growth factor (EGF)-like proteins stimulates cells to divide by activating members…
c-Met (hepatocyte growth factor receptor, HGFR) is a type of receptor tyrosine kinase which belongs to the MET family. c-Met exsists in the surfaces of various epithelial cells. Hepatocyte growth…
Receptor tyrosine kinase FMS like tyrosine kinase 3 (FLT3) is a member of the class III receptor tyrosine kinase family. The family also includes FMS, kit, and platelet-derived growth factor…
Acute myelogenous leukemia (AML) is a devastating hematologic cancer with limited treatments. Scientists have demonstrated that diverse genetic changes are associated with AML. Especially, the upregulation of tyrosine kinase signaling…
VEGF signaling via VEGF receptor is a pivotal factor for tumor angiogenesis that regulates tumor progression. However, VEGFR-targeted inhibitor monotherapies showed limited effects on various carcinomas. And even combination therapies with…
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. While the application of targeted tyrosine kinase inhibitors has revolutionized the treatment of gastrointestinal stromal tumors…